Kwangdong Healthbio광동헬스바이오
086220 · KONEX · ₩086220 · 광동헬스바이오
₩1,179▼ ₩10 (0.84%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 7.6% | 7.6% | 4.3% | 7.7% | 7.6% | 7.6% |
| Operating margin | 1.3% | 1.3% | −1.5% | 3.3% | 2.4% | 1.5% |
| Net margin | −1.0% | −1.0% | −3.0% | 0.7% | 1.1% | 0.8% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +2.3% | +2.3% | −18.3% | +25.4% | +10.6% | — |
| Operating income growth | +190.3% | +190.3% | −137.9% | +68.0% | +84.5% | — |
| Net income growth | +67.3% | +67.3% | −443.8% | −18.6% | +59.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −3.7% | −3.7% | −11.5% | 3.2% | 4.1% | 2.6% |
| Return on assets | −1.1% | −1.1% | −3.6% | 1.0% | 1.2% | 0.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 240.1% | 240.1% | 232.4% | 215.2% | 216.4% | 263.5% |
| Net debt to equity | 97.2% | 97.2% | 141.7% | 129.3% | 151.4% | 155.5% |
| Current ratio | 82.2% | 82.2% | 73.1% | 68.8% | 57.8% | 64.6% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Kwangdong Healthbio / 광동헬스바이오 / 086220 / KRX:086220
Source: KRX statistical information